RecruitingPhase 2Phase 3NCT05431088

A Phase 2/3 Study in Adult and Adolescent Participants With SCD

A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Adult and Adolescent Participants With Sickle Cell Disease

Sponsor

Pfizer

Enrollment

389 participants

Start Date

Sep 22, 2022

Study Type

INTERVENTIONAL

Conditions

Sickle Cell Disease

Summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Osivelotor for people with sickle cell disease. The study is currently recruiting participants at 49 locations. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOsivelotor

Tablets which contain drug substance

Locations(49)

Smilow Cancer Hospital

New Haven, Connecticut, United States

Edward Jenner Research Group Center LLC

Plantation, Florida, United States

Pediatric Hematology / Oncology a division of Kidz Medical services

West Palm Beach, Florida, United States

St. Mary's Medical Center

West Palm Beach, Florida, United States

Alpha Clinical Research Georgia

Dunwoody, Georgia, United States

Sonar Clinical Research

Riverdale, Georgia, United States

University of Illinois at Chicago Clinical Research Center

Chicago, Illinois, United States

University of Illinois Hospital and Health Sciences System - Investigational Drug Services (IDS)

Chicago, Illinois, United States

University of Illinois Hospital and Health Sciences System

Chicago, Illinois, United States

LSU Health Baton Rouge-North Clinic

Baton Rouge, Louisiana, United States

Our Lady of the Lake Hospital, Inc.

Baton Rouge, Louisiana, United States

Our lady of the Lake Hospital

Baton Rouge, Louisiana, United States

University Medical Center New Orleans

New Orleans, Louisiana, United States

Mississippi Center for Advanced Medicine

Madison, Mississippi, United States

University Health

Kansas City, Missouri, United States

Clinical & Translational Research Center (CTRC)

Chapel Hill, North Carolina, United States

UNC Health

Chapel Hill, North Carolina, United States

UNC Eastowne Medical Office Building - Consent Only

Chapel Hill, North Carolina, United States

UNC IDS

Morrisville, North Carolina, United States

McGovern Medical School at UTHealth

Houston, Texas, United States

Memorial Hermann Hospital, Texas Medical Center - Clinical Research Unit (CRU)

Houston, Texas, United States

The University of Texas Health Science Center at Houston

Houston, Texas, United States

UT Physicians Comprehensive Sickle Cell Clinic

Houston, Texas, United States

Inova Schar Cancer Institute

Fairfax, Virginia, United States

Hospital Universitario Professor Edgar Santos

Salvador, Estado de Bahia, Brazil

Multihemo Servicos Medicos S/A

Recife, Pernambuco, Brazil

Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP

Ribeirão Preto, São Paulo, Brazil

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto

São José do Rio Preto, São Paulo, Brazil

BP A Beneficência Portuguesa de São Paulo

São Paulo, São Paulo, Brazil

BP - A Beneficência Portuguesa de São Paulo

São Paulo, São Paulo, Brazil

Casa de Saude Santa Marcelina

São Paulo, São Paulo, Brazil

Casa de Saude Santa Marcelina

São Paulo, São Paulo, Brazil

Esho Empresa de Servicos Hospitalares S A

São Paulo, SÃO Paulo- Brasil, Brazil

Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO

Rio de Janeiro, Brazil

Esho Empresa de Servicos Hospitalares S A

São Paulo, Brazil

Real e Benemerita Associacao Portuguesa de Sao Paulo

São Paulo, Brazil

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo

São Paulo, Brazil

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo

São Paulo, Brazil

Nirmal Hospital Pvt Ltd

Surat, Gujarat, India

Chopda Medicare & Research Centre Pvt. Ltd: Magnum Heart Institute

Nashik, Maharashtra, India

KEMRI/CRDR, Siaya, KEMRI Clinical Research Annex

Kisumu, Siaya County, Kenya

Gertrude's Children's Hospital

Nairobi, Kenya

Kenya Medical Research Institute - Centre for Respiratory Disease Research

Nairobi, Kenya

Center for Research In Therapeutic Sciences (CREATES), Strathmore University Medical Centre

Nairobi, Kenya

University College Hospital Ibadan

Ibadan, Oyo/ibadan North, Nigeria

Aminu Kano Teaching Hospital

Kano, Nigeria

Lagos University Teaching Hospital

Lagos, Nigeria

University Hospitals Bristol and Weston NHS Foundation Trust

Bristol, United Kingdom

Bristol Royal Infirmary

Bristol, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05431088

Related Trials

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT0643908232 locations

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT065466709 locations

A Phase 2/3 Study in Adult and Adolescent Participants With SCD

Conditions

Summary

Eligibility

Plain Language Summary

Interventions

Locations(49)

Related Trials

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Blood Sampling for Research Related to Sickle Cell Disease

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease